NNOX: Reset Expectations And New Distribution Deals Could Support Upside

Analysts have trimmed their fair value estimate for Nano-X Imaging to $6.65 from $7.75 as they factor in updated assumptions around discount rates, long term revenue growth, profit margins, and future P/E levels.

Analyst Commentary

Recent research has reset expectations around Nano-X Imaging, with analysts revisiting key inputs such as discount rates, long term revenue assumptions, margin potential, and future P/E levels. The latest published price target move, a US$2 reduction flagged in recent Street research, sits alongside these broader valuation changes.

Here is how bullish and bearish analysts are framing the setup around the new fair value estimate of US$6.65.

Bullish Takeaways

Bullish analysts view the updated fair value as a refreshed entry reference that already incorporates more conservative discount rate and P/E assumptions, which they see as helpful for resetting expectations.
Some highlight that the valuation work still assigns value to Nano-X Imaging's potential to scale revenue over the long term, even with tempered growth and margin inputs.
Supportive views point out that the reduced target is driven by model assumptions rather than any new disclosed change in the business, which they consider more of a technical reset than a fundamental reassessment.
Bullish analysts argue that, with a lower bar embedded in the numbers, execution on commercialization or cost control could have a clearer path to being reflected in future valuation updates.

Bearish Takeaways

Bearish analysts focus on the cut in the price target, including the US$2 reduction highlighted in recent research, as a sign that prior expectations for growth, profitability, or achievable P/E multiples may have been too optimistic.
Some express concern that the need to adjust discount rates and long term revenue growth assumptions signals increased uncertainty around how quickly Nano-X Imaging can scale its model.
More cautious views question the sustainability of the margin profile implied in earlier forecasts, leading them to apply tighter profit and valuation assumptions today.
Bearish analysts also warn that if execution around adoption, regulatory progress, or cost structure lags the updated models, further revisions to fair value cannot be ruled out.

What’s in the News

Nano-X Imaging’s U.S. subsidiary, Nanox Impact Inc., signed a distribution agreement with Radiology Oncology Systems to distribute the FDA-cleared Nanox.ARC multisource digital tomosynthesis system across U.S. hospitals and clinics. The agreement will use Radiology Oncology Systems’ national network and service infrastructure to support deployment. (Company announcement)
The company appointed Guy Nathanzon as Chief Financial Officer effective August 1, 2026. Current CFO Ran Daniel will step down July 31, 2026, and remain through a transition period. The company indicated there is no disagreement on operations or policies related to his departure. (Executive changes)
Nano-X Imaging issued full year 2026 revenue guidance, targeting US$35 million based on its current operational plans and assumptions. (Corporate guidance)
The company recorded impairment charges of US$17,528,000 on long lived assets for the quarter ended December 31, 2025. (Impairment disclosure)
Nano-X Imaging reported multiple new Nanox.ARC distribution agreements, including with Elite Surgical Technologies across several U.S. states, Imperial Imaging Technology across the U.S. Southeast, and Intec SRL as exclusive distributor in Argentina. These agreements are focused on supporting commercialization of its multisource digital tomosynthesis systems in clinical settings. (Company announcements)

Valuation Changes

Fair Value: trimmed from $7.75 to $6.65, a reduction of $1.10 in the updated model.
Discount Rate: moved slightly higher from 8.34% to 8.45%, implying a modestly higher required return.
Revenue Growth: revised from 82.80% to 103.62%, indicating a higher modeled growth rate for future revenue.
Net Profit Margin: adjusted from 5.39% to 5.12%, a small reduction in expected long term profitability.
Future P/E: reset from 196.41x to 128.12x, reflecting a meaningfully lower valuation multiple assumption.

16 views

Key Takeaways

Global expansion and scalable manufacturing are set to boost long-term revenue growth, increase market share, and drive sustainable margin improvements.
Innovative AI-enabled, cost-effective imaging offerings are positioned to expand addressable markets and generate new high-margin recurring revenue streams.
Slow adoption of core imaging technology, ongoing losses, heavy reliance on teleradiology, regulatory hurdles, and high spending threaten profitability and growth prospects.

Catalysts

About Nano-X Imaging

Develops a commercial-grade tomographic imaging device with a digital X-ray source.What are the underlying business or industry changes driving this perspective?

Rapid progress toward commercial deployment, with a clear pipeline to install 100 Nanox.ARC systems by year-end, is expected to significantly increase revenue in the second half of 2025 and beyond, especially as a growing number of units begin active scanning and utilization.
Expansion into new geographies-including rapid entry into Europe post-CE Mark and upcoming launches in Romania, Greece, and Latin America-aligns with rising global healthcare investment in emerging markets, driving long-term revenue growth and global market share.
Integration of AI and cloud-based teleradiology solutions through collaborations with academic centers and commercial partners is positioning Nano-X to benefit from the healthcare sector's shift towards digital diagnostics, which is likely to boost recurring revenue, improve gross margins, and support adoption in regions with radiologist shortages.
The development of cost-effective, portable, and mobile imaging offerings-such as the mobile Nanox.ARC vehicle-directly addresses the need for affordable, accessible imaging (especially amid global population aging), which should expand the company's addressable market and create new high-margin service streams.
Recent agreements for scalable manufacturing and supply chain robustness (e.g., partnership with Fabrinet) are set to lower production costs, support margin expansion, and mitigate operational risks, providing a pathway for sustainable improvements in net margins as commercial sales grow.

Nano-X Imaging Earnings and Revenue Growth

Nano-X Imaging Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Nano-X Imaging's revenue will grow by 103.6% annually over the next 3 years.
Analysts are not forecasting that Nano-X Imaging will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Nano-X Imaging's profit margin will increase from -576.1% to the average US Healthcare industry of 5.1% in 3 years.
If Nano-X Imaging's profit margin were to converge on the industry average, you could expect earnings to reach $5.6 million (and earnings per share of $0.07) by about April 2029, up from -$75.0 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 128.5x on those 2029 earnings, up from -1.6x today. This future PE is greater than the current PE for the US Healthcare industry at 24.3x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.45%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Despite steady progress in system installations, only about 20 out of over 60 installed Nanox.ARC units were actually operational and scanning patients in Q2 2025, indicating slow commercial adoption and utilization, which negatively impacts near-term revenue growth and raises doubts about achieving scale and pathway to profitability.
Nanox continues to incur significant net losses ($14.7 million in Q2 2025 versus $13.6 million in Q2 2024), with gross margins on core imaging system sales and AI solutions remaining negative, suggesting a high risk of prolonged unprofitability and continued cash burn that could lead to additional capital raises and potential shareholder dilution.
The company's revenue growth remains heavily reliant on teleradiology services, which are not the core novel technology offering, while revenues from imaging system sales and AI solutions stay minimal and volatile, highlighting execution risk and potential overreliance on a commoditized service line that could constrain future earnings quality and consistency.
Regulatory clearance and adoption remain highly region-dependent, with U.S. operations reportedly approved in only eight states and many global market launches still pending import permits or certifications, indicating long-term regulatory and commercialization uncertainty that could limit global revenue opportunities and delay scale.
High R&D and sales and marketing spending, combined with slow revenue ramp-up from new product lines, poses a challenge to improving net margins and raises questions about the company's ability to achieve operational leverage, especially if evolving healthcare reimbursement or competitive activity delays broader acceptance and monetization of its technology.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $6.65 for Nano-X Imaging based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $9.6, and the most bearish reporting a price target of just $5.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $109.9 million, earnings will come to $5.6 million, and it would be trading on a PE ratio of 128.5x, assuming you use a discount rate of 8.4%.
Given the current share price of $1.74, the analyst price target of $6.65 is 73.9% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Nano-X Imaging?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Digital Diagnostics And AI Will Open Global Markets